Q2 2021 Coloplast A/S Earnings Call Transcript
Welcome to the Coloplast Q2 Conference Call. (Operator Instructions) Please note, this call is being recorded. I'll now hand the floor to our speakers in your meeting.
/-&
Good afternoon, and welcome to our first half 2021 conference call. My name is Kristian Villumsen, CEO of Coloplast, and I'm joined by our CFO, Anders Lonning-Skovgaard and our Investor Relations team. We'll start with a short presentation by Anders and myself, like we usually do, and then we'll open up for questions.
Please turn to Slide #3. After an encouraging start to the year in Q1, we had expected a weaker second quarter due to a large stocking impact in our baseline and the continued negative impact of COVID-19 on our European Chronic Care business. We delivered 2% organic growth, a 33% EBIT margin before special items and a return on invested capital before special items of 42%. Adjusted for the DKK 150 million stocking effect in Q2 of last year, organic growth was around 5% for
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |